Novartis’ Fabhalta Shows Promise in Slowing Rare Kidney Disease
Novartis has announced strong results for its drug Fabhalta (iptacopan). The treatment slowed the progression of IgA nephropathy, a rare and serious kidney disease, in a major clinical trial. In the Phase III study, patients taking Fabhalta had a much slower loss of kidney function compared to those on placebo. The drug improved the eGFR…